56 related articles for article (PubMed ID: 10741729)
1. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Teicher BA; Chen V; Shih C; Menon K; Forler PA; Phares VG; Amsrud T
Clin Cancer Res; 2000 Mar; 6(3):1016-23. PubMed ID: 10741729
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with nedaplatin and cyclophosphamide in human ovarian cancer model.
Uchida N; Yoshida H; Yamada H; Wada T; Daikatsu K; Ikeuchi I; Maekawa R; Sugita K; Yoshioka T
Jpn J Cancer Res; 1999 Aug; 90(8):887-94. PubMed ID: 10543262
[TBL] [Abstract][Full Text] [Related]
3. Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
Mariniello A; Nasti TH; Chang DY; Hashimoto M; Malik S; McManus DT; Lee J; McGuire DJ; Cardenas MA; Umana P; Nicolini V; Antia R; Saha A; Buchwald Z; Kissick H; Ghorani E; Novello S; Sangiolo D; Scagliotti GV; Ramalingam SS; Ahmed R
Clin Cancer Res; 2024 May; 30(9):1833-1845. PubMed ID: 37992307
[TBL] [Abstract][Full Text] [Related]
4. Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells.
Ko JC; Chen JC; Tseng PY; Hsieh JM; Chiang CS; Liu LL; Chien CC; Huang IH; Lin YW
Toxicol Res (Camb); 2022 Apr; 11(2):299-310. PubMed ID: 35510237
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel thymidylate synthase (TS) inhibitor capable of up-regulating P53 expression and inhibiting angiogenesis in NSCLC.
Li XY; Wang DP; Lu GQ; Liu KL; Zhang TJ; Li S; Mohamed O K; Xue WH; Qian XH; Meng FH
J Adv Res; 2020 Nov; 26():95-110. PubMed ID: 33133686
[TBL] [Abstract][Full Text] [Related]
6. Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity.
Li XY; Zhang TJ; Kamara MO; Lu GQ; Xu HL; Wang DP; Meng FH
Cell Death Dis; 2019 Jul; 10(7):532. PubMed ID: 31296849
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Murine Models for Lung Cancer: Clinical Trial Applications.
Kellar A; Egan C; Morris D
Biomed Res Int; 2015; 2015():621324. PubMed ID: 26064932
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed induces S-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway.
Chen KC; Yang TY; Wu CC; Cheng CC; Hsu SL; Hung HW; Chen JW; Chang GC
PLoS One; 2014; 9(5):e97888. PubMed ID: 24847863
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer.
Ho C; Davies AM; Sangha RS; Lau D; Lara P; Chew HK; Beckett L; Mack PC; Riess JW; Gandara DR
Invest New Drugs; 2013 Dec; 31(6):1587-91. PubMed ID: 24013936
[TBL] [Abstract][Full Text] [Related]
10. Effect of folic acid and vitamin B12 on pemetrexed antifolate chemotherapy in nutrient lung cancer cells.
Yang TY; Chang GC; Hsu SL; Huang YR; Chiu LY; Sheu GT
Biomed Res Int; 2013; 2013():389046. PubMed ID: 23984356
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells.
Chen RS; Ko JC; Chiu HC; Wo TY; Huang YJ; Tseng SC; Chen HJ; Huang YC; Jian YJ; Lee WT; Lin YW
Naunyn Schmiedebergs Arch Pharmacol; 2013 Dec; 386(12):1047-59. PubMed ID: 23912706
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells.
Buqué A; Muhialdin JSh; Muñoz A; Calvo B; Carrera S; Aresti U; Sancho A; Rubio I; López-Vivanco G
Mol Cancer; 2012 Apr; 11():25. PubMed ID: 22537194
[TBL] [Abstract][Full Text] [Related]
13. Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma.
Shen X; Denittis A; Werner-Wasik M; Axelrod R; Gilman P; Meyer T; Treat J; Curran WJ; Machtay M
Radiat Oncol; 2011 Feb; 6():17. PubMed ID: 21324160
[TBL] [Abstract][Full Text] [Related]
14. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.
Wouters A; Pauwels B; Lardon F; Pattyn GG; Lambrechts HA; Baay M; Meijnders P; Vermorken JB
BMC Cancer; 2010 Aug; 10():441. PubMed ID: 20723210
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
Richards DA; Loesch D; Vukelja SJ; Wu H; Hyman WJ; Nieves J; Wang Y; Hu S; Shonukan OO; Tai DF
Invest New Drugs; 2011 Oct; 29(5):963-70. PubMed ID: 20352294
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.
Xu X; Prestwich GD
Cancer; 2010 Apr; 116(7):1739-50. PubMed ID: 20143443
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer.
Baldwin CM; Perry CM
Drugs; 2009 Nov; 69(16):2279-302. PubMed ID: 19852529
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
Sanoff HK; Davies J; Walko C; Buie L; Chiu WK; Ivanova A; O'Neil B; Stinchcombe TE; Keller K; Dees EC
Invest New Drugs; 2011 Feb; 29(1):131-6. PubMed ID: 19830387
[TBL] [Abstract][Full Text] [Related]
19. Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma.
Goudar RK
Ther Clin Risk Manag; 2008 Feb; 4(1):205-11. PubMed ID: 18728709
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.
Stover DG; Lockhart AC; Berlin JD; Chan E; Sandler AB; Sosman JA; Middlebrook V; Nicol S; Rothenberg ML
Invest New Drugs; 2008 Aug; 26(4):339-45. PubMed ID: 18463792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
